Dyadic International (NASDAQ:DYAI), Inc. is a biotechnology company focused on developing and commercializing microbial protein-expression technologies for the production of biologic products. Its platforms are designed to enable the efficient development and manufacture of proteins used in vaccines, therapeutics, food and nutrition products, and industrial applications.
The company’s principal technology, the C1 expression platform, is based on a proprietary strain of the fungus Trichoderma reesei. Dyadic has also developed additional microbial systems, including the Dapibus platform, which is intended to support the production of proteins and other biological materials in yeast. These technologies may be used by Dyadic and its partners to develop recombinant proteins, antibodies, enzymes, antigens, and other products.
Dyadic works with pharmaceutical, biotechnology, food, and industrial organizations through research collaborations, licensing arrangements, and technology partnerships. The company serves a global market and has historically emphasized applications that could offer scalable and cost-effective alternatives to conventional mammalian-cell manufacturing. Dyadic International is headquartered in Jupiter, Florida, and was founded by Mark Emalfarb, who has served as the company’s chief executive officer.
